Teucrium Corn Fund vs Medpace Holdings Inc — how do they compare? Teucrium Corn Fund trades at $18.99 (market cap $125.39M), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 134.1× Teucrium Corn Fund's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 26 Days and Medpace Holdings Inc for 14 Days on average.
| CORN | MEDP | |
|---|---|---|
Market Cap | $125.39M | $16.82B |
Volume | 271,634 | 223,093 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $630.19 |
52-Week Low | $16.46 | $393.42 |
Typical Hold Time | 26 Days | 14 Days |
Enterprise Value | — | $16.44B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →